Adverum Biotechnologies, Inc.
Clinical trials sponsored by Adverum Biotechnologies, Inc., explained in plain language.
-
One-shot gene therapy could cut eye injections for wet AMD
Disease control Recruiting nowThis phase 3 study tests a single injection of Ixo-vec gene therapy in 284 people with wet age-related macular degeneration (nAMD). The goal is to see if Ixo-vec can maintain or improve vision as well as standard aflibercept injections, but with fewer follow-up injections. Partic…
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
One shot to save sight? gene therapy trial aims to end frequent eye injections for wet AMD
Disease control Recruiting nowThis phase 3 study tests a single injection of a gene therapy called Ixo-vec for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if this one-time treatment can maintain or improve vision as well as standard care (afliberc…
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC